嗅素蛋白4调控免疫炎性反应的研究进展

doi:10.16352/j.issn.1001-6325.2026.04.0587

基础医学与临床 ›› 2026, Vol. 46 ›› Issue (4): 587-591.doi: 10.16352/j.issn.1001-6325.2026.04.0587

嗅素蛋白4调控免疫炎性反应的研究进展

武懿, 夏丽坤^*

中国医科大学附属盛京医院眼科, 辽宁沈阳 110004

收稿日期:2025-01-15 修回日期:2025-06-23 发布日期:2026-03-24
通讯作者: ^*xialk@sj-hospital.org
基金资助:
辽宁省科技厅应用基础研究计划项目(2022JH2/101300044)

Research progress of olfactomedin 4 in regulating immune inflammatory response

WU Yi, XIA Likun^*

Department of Ophthalmology, Shengjing Hospital of China Medical University,Shenyang 110004,China

Received:2025-01-15 Revised:2025-06-23 Published:2026-03-24
Contact: ^*xialk@sj-hospital.org

摘要/Abstract

摘要： 嗅素蛋白4(OLFM4)是一种嗅素结构域家族糖蛋白,在免疫调节、细胞凋亡与对抗微生物感染等方面发挥重要作用,能够影响免疫细胞、上皮细胞及肿瘤细胞的激活、迁移及凋亡,与多个信号转导通路因子包括β-catenin、NF-κB、STAT3、MAPK和cGAS-STING等存在重要关联。近年来,随着对OLFM4研究的深入,发现OLFM4的异常表达与感染性疾病、肿瘤发展以及多种炎性疾病的预后密切相关,这提示其有望成为疾病早期生物标志物以及临床治疗药物的潜在靶点。

关键词: 嗅素蛋白4, 免疫调控, 炎性反应, 信号通路

Abstract: Olfactomedin 4 (OLFM4) is an olfactomedin domain family glycoprotein that plays an important role in immune regulation, cell apoptosis and anti-microbial infection. It can affect the activation, migration and apoptosis of immune cells, epithelial cells and tumor cells. OLFM4 has important relationships with multiple signal transduction pathway factors, including β-catenin,NF-κB,STAT3,MAPK and cGAS-STING. In recent years, with advancing research on OLFM4, it has been found that the abnormal expression of OLFM4 is closely related to the prognosis of infectious diseases, tumor development and a variety of inflammatory diseases, which suggests that OLFM4 is a potential early biomarker for diseases and a potential target for clinical therapeutics.

Key words: olfactomedin 4, immune regulation, inflammatory response, signaling pathway

中图分类号:

R392

武懿, 夏丽坤. 嗅素蛋白4调控免疫炎性反应的研究进展[J]. 基础医学与临床, 2026, 46(4): 587-591.

WU Yi, XIA Likun. Research progress of olfactomedin 4 in regulating immune inflammatory response[J]. Basic & Clinical Medicine, 2026, 46(4): 587-591.

参考文献

[1] Zhang J, Liu WL, Tang DC, et al. Identification and characterization of a novel member of olfactomedin-related protein family, hGC-1, expressed during myeloid lineage development[J]. Gene, 2002, 283: 83-93.doi:10.1016/s0378-1119(01)00763-6.
[2] Liu W, Chen L, Zhu J, et al. The glycoprotein hGC-1 binds to cadherin and lectins[J]. Exp Cell Res, 2006, 312: 1785-1797.doi:10.1016/j.yexcr.2006.02.011.
[3] Zou Y, Kamada N, Seong SY, et al. CD115(-) monocytic myeloid-derived suppressor cells are precursors of OLFM4(high) polymorphonuclear myeloid-derived suppressor cells[J]. Commun Biol, 2023, 6: 272.doi:10.1038/s42003-023-04650-3.
[4] Chen Z, Zhang X, Xing Z, et al. OLFM4 deficiency delays the progression of colitis to colorectal cancer by abrogating PMN-MDSCs recruitment[J]. Oncogene, 2022, 41: 3131-3150.doi:10.1038/s41388-022-02324-8.
[5] Jabeen A, Ahmad N, Raza K. Global gene expression and docking profiling of COVID-19 infection[J]. Front Genet, 2022, 13: 870836.doi:10.3389/fgene.2022.870836.
[6] Xu K, Zheng P, Zhao S, et al. LRFN5 and OLFM4 as novel potential biomarkers for major depressive disorder: a pilot study[J]. Transl Psychiatry, 2023, 13: 188.doi:10.1038/s41398-023-02490-7.
[7] Zhang F, Li Y, Xi Y, et al. Qinbaohong Zhike oral liquid attenuates LPS-induced acute lung injury in immature rats by inhibiting OLFM4[J]. Oxid Med Cell Longev, 2022, 2022: 7272371.doi:10.1155/2022/7272371.
[8] Vandenberghe-Durr S, Gilliet M, Di Domizio J. OLFM4 regulates the antimicrobial and DNA binding activity of neutrophil cationic proteins[J]. Cell Rep, 2024, 43: 114863.doi:10.1016/j.celrep.2024.114863.
[9] Novak T, Crawford JC, Hahn G, et al. Transcriptomic profiles of multiple organ dysfunction syndrome phenotypes in pediatric critical influenza[J]. Front Immunol, 2023, 14: 1220028.doi:10.3389/fimmu.2023.1220028.
[10] 王启源, 姬文兰, 虞秀锋. 嗅素蛋白4对卡介苗诱导巨噬细胞凋亡和细菌胞内生存率的影响[J]. 检验医学, 2020, 35: 818-822.doi:10.3969/j.issn.1673-8640.2020.08.017.
[11] He H, Chen S, Yu Y, et al. Comprehensive single-cell analysis deciphered microenvironmental dynamics and immune regulator olfactomedin 4 in pathogenesis of gallbladder cancer[J]. Gut, 2024, 73: 1529-1542.doi:10.1136/gutjnl-2023-331773.
[12] Baek BS, Park H, Choi JW, et al. Dendritic cells pulsed with penetratin-OLFM4 inhibit the growth and metastasis of melanoma in mice[J]. Biomed Pharmacother, 2024, 177: 117083.doi:10.1016/j.biopha.2024.117083.
[13] Wei H, Li W, Zeng L, et al. OLFM4 promotes the progression of intestinal metaplasia through activation of the MYH9/GSK3beta/beta-catenin pathway[J]. Mol Cancer, 2024, 23: 124.doi:10.1186/s12943-024-02016-9.
[14] Huang J, Xu Z, Jiao J, et al. Microfluidic intestinal organoid-on-a-chip uncovers therapeutic targets by recapitulating oxygen dynamics of intestinal IR injury[J]. Bioact Mater, 2023, 30: 1-14.doi:10.1016/j.bioactmat.2023.07.001.
[15] Ashizawa Y, Kuboki S, Nojima H, et al. OLFM4 enhances STAT3 activation and promotes tumor progres-sion by inhibiting GRIM19 expression in human hepatocellular carcinoma[J]. Hepatol Commun, 2019, 3: 954-970.doi:10.1002/hep4.1361.
[16] Tang Z, Wei C, Deng X, et al. Serum proteomic and metabolomic profiling of hepatocellular carcinoma patients co-infected with Clonorchis sinensis[J]. Front Immunol, 2024, 15: 1489077.doi:10.3389/fimmu.2024.1489077.
[17] Liu W, Li H, Aerbajinai W, et al. OLFM4-RET fusion is an oncogenic driver in small intestine adenocarcinoma[J]. Oncogene, 2022, 41: 72-82.doi:10.1038/s41388-021-02072-1.
[18] Xing Z, Li X, He J, et al. OLFM4 modulates intestinal inflammation by promoting IL-22(+)ILC3 in the gut[J]. Commun Biol, 2024, 7: 914.doi:10.1038/s42003-024-06601-y.
[19] Chen C, Xu P. Cellular functions of cGAS-STING signaling[J]. Trends Cell Biol, 2023, 33: 630-648.doi:10.1016/j.tcb.2022.11.001.
[20] Wen F, Han Y, Zhang H, et al. Epstein-Barr virus infection upregulates extracellular OLFM4 to activate YAP signaling during gastric cancer progression[J]. Nat Commun, 2024, 15: 10543.doi:10.1038/s41467-024-54850-6.

嗅素蛋白4调控免疫炎性反应的研究进展

Research progress of olfactomedin 4 in regulating immune inflammatory response

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘翠玲, 于树娜. NLRP3炎性小体在肝缺血/再灌注损伤中作用的研究进展[J]. 基础医学与临床, 2026, 46(7): 1004-1008.
[2]	王勇豪, 张卓钰, 苏铭恒, 张琪. 外泌体在卒中后认知障碍诊疗中的研究进展[J]. 基础医学与临床, 2026, 46(6): 861-865.
[3]	张腾宇, 吴婷, 吴祥. 视黄酸在认知障碍类疾病中的研究进展[J]. 基础医学与临床, 2026, 46(5): 717-720.
[4]	尹静, 陈春玲. 神经炎性反应介导的术后认知功能障碍的研究进展[J]. 基础医学与临床, 2026, 46(4): 602-606.
[5]	宋宁, 罗俊一, 冀伟, 李艳红, 李晓梅, 杨毅宁. 敲降MALAT1减轻ox-LDL诱导的巨噬细胞炎性反应和细胞损伤[J]. 基础医学与临床, 2026, 46(3): 352-358.
[6]	林清, 杨斌, 朱榕嘉, 赵春华, 宋坪. 淫羊藿苷通过抑制PI3K-AKT-血管增生治疗模型小鼠银屑病[J]. 基础医学与临床, 2026, 46(3): 311-316.
[7]	任磊磊, 吕钰麟, 王浩骅, 张婉君, 孟姝, 姜明红. 皮肌炎患者NK细胞衰老介导其“高炎性反应-弱抗感染”的矛盾表型[J]. 基础医学与临床, 2026, 46(3): 345-351.
[8]	何萍, 王艳. Isthmin-1对糖脂代谢的调控作用及其临床意义[J]. 基础医学与临床, 2026, 46(3): 445-449.
[9]	陈梦蕾, 崔云. Notch信号通路在支气管哮喘中的作用[J]. 基础医学与临床, 2026, 46(2): 293-297.
[10]	崔宇頔, 张丰川, 李元文, 杨碧莲. 青石止痒软膏减轻咪喹莫特诱导的银屑病小鼠皮肤损伤[J]. 基础医学与临床, 2026, 46(2): 164-169.
[11]	张兆波, 张文岭, 赵飞飞, 杜国涛. 灰树花多糖改善地塞米松诱导的小鼠骨骼肌细胞系C2C12模型肌管的萎缩[J]. 基础医学与临床, 2026, 46(1): 56-62.
[12]	屈改茹, 席世兵, 张宗丽, 李涛. 槲皮素抑制TNF-α诱导的小鼠主动脉血管平滑肌细胞系MOVAS炎性反应[J]. 基础医学与临床, 2026, 46(1): 78-84.
[13]	刘婷婷, 郜玲, 李筱妍. 中性粒细胞胞外诱捕网在脓毒症诱导的急性呼吸窘迫综合征中的研究进展[J]. 基础医学与临床, 2026, 46(1): 139-143.
[14]	高彦东, 边步荣, 王波. 异丙酚减轻结扎脊神经诱导的大鼠神经病理性疼痛[J]. 基础医学与临床, 2025, 45(8): 1028-1033.
[15]	贾纯亮, 梁磊, 李翰嵩, 王剑, 张磊, 李青科, 姚远. 灯盏花乙素抑制人胃癌细胞系MGC803增殖和迁移[J]. 基础医学与临床, 2025, 45(8): 1048-1053.